世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

臨床試験サプライ&ロジスティクス市場規模、シェア、動向分析レポート:サービス別(ロジスティクス&流通、保管&リテンション)、フェーズ別、治療領域別、エンドユース別、地域別、セグメント別予測、2024年〜2030年


Clinical Trial Supply & Logistics Market Size, Share & Trends Analysis Report By Service (Logistics & Distribution, Storage & Retention), By Phase, By Therapeutic Area, By End-use, By Region, And Segment Forecasts, 2024 - 2030

臨床試験サプライ&ロジスティクス市場の成長と動向 Grand View Research, Inc.の最新レポートによると、世界の臨床試験サプライ&ロジスティクス市場規模は、2024年から2030年にかけて7.6%のCAGRを記録し、20... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
Grand View Research
グランドビューリサーチ
2023年12月27日 US$5,950
シングルユーザライセンス(印刷不可)
ライセンス・価格情報
注文方法はこちら
137 英語

1~3営業日


 

サマリー

臨床試験サプライ&ロジスティクス市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界の臨床試験サプライ&ロジスティクス市場規模は、2024年から2030年にかけて7.6%のCAGRを記録し、2030年までに62億5000万米ドルに達すると予測されている。臨床試験サプライ&ロジスティクス市場における先端技術やイノベーションの台頭、厳格な規制の実施、COVID-19パンデミックのような疾患の流行増加による臨床試験需要の高まりが背景にある。

当初、COVID-19パンデミックは、サプライチェーンの混乱や、ウイルスの蔓延を防ぐための政府による民間航空会社の削減により、市場にマイナスの影響を与えた。しかし、この病気を予防するためのCOVID-19ワクチンに対する需要の高まりにより、市場はすぐに回復し、大きく成長し始めた。例えば、WHOによると、2022年8月2日現在、臨床開発段階にあるワクチンは169種類、前臨床段階にあるワクチンは198種類ある。

臨床試験用品プロバイダーによるサプライチェーンマネジメント・ソフトウェアへの投資は著しい。臨床試験の複雑化と市場参入企業間の競争激化が、サプライチェーン管理に新技術を採用する要因となっている。在庫管理、サプライチェーンプランニング、補助的なサプライチェーンマネジメントのためのソフトウェアのニーズは、業界プレーヤーによる新技術採用の増加により、拡大すると予想される。

臨床試験サプライ&ロジスティクス市場レポートハイライト

- サービス分野では、ロジスティクスと流通が2023年の市場シェアを25.33%で独占した。これは、COVID- 19パンデミックによる臨床試験の増加によるものである。

- フェーズ別では、フェーズIIIが2023年に最大の売上シェアを占める

- 治療領域別では、心血管疾患が予測期間中最速のCAGR 8.0%を占めた。これは、市場に新規性と革新性をもたらすための市場参入企業による投資件数の増加によるものである。

- アジア太平洋地域は予測期間中に8.1%の最速成長率を記録すると予測される。これは、採用コストが低いこと、多様で大規模な患者プールを利用できること、臨床試験に望ましい有利な政策によるものである。

ページTOPに戻る


目次

Table of Contents

Chapter 1. Methodology And Scope
1.1. Market Segmentation And Scope
1.1.1. Segment Definitions
1.1.1.1. Service Segment
1.1.1.2. Phase Segment
1.1.1.3. Therapeutics Area Segment
1.1.1.4. End use segment
1.2. Regional Scope
1.3. Estimates And Forecast Timeline
1.4. Objectives
1.4.1. Objective - 1
1.4.2. Objective - 2
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. GVR’s Internal Database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information Or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.10. List Of Primary Sources
1.11. List Of Abbreviations
Chapter 2. Clinical Trial Supply & Logistics Market: Executive Summary
2.1. Market Snapshot
2.2. Services And Phase Snapshots
2.3. Therapeutic Area And End Use Snapshot
2.4. Competitive Landscape Snapshot
Chapter 3. Clinical Trial Supply & Logistics Market Variables, Trends, & Scope
3.1. Market Segmentation And Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.4. Market Drivers Analysis
3.4.1. Technological advancements in supply chain
3.4.2. Increasing R&D investment by pharmaceutical and biopharmaceutical firms
3.4.3. Expansion of clinical trial sites
3.5. Market Restraint Analysis
3.5.1. Stringent regulation pertaining to logistics.
3.5.2. Counterfeiting of drugs
3.6. Clinical Trial Supply & Logistics Market Analysis Tools
3.6.1. Industry Analysis - Porter’s
3.6.1.1. Supplier Power
3.6.1.2. Buyer Power
3.6.1.3. Substitution Threat
3.6.1.4. Threat Of New Entrant
3.6.1.5. Competitive Rivalry
3.6.2. PESTLE Analysis
3.6.2.1. Political Landscape
3.6.2.2. Technological Landscape
3.6.2.3. Economic Landscape
Chapter 4. Clinical Trial Supply & Logistics: Service Estimates & Trend Analysis
4.1. Service Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. Global Clinical Trial Supply & Logistics Market By Service Outlook
4.4. Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Following
4.4.1. Logistics & Distribution
4.4.1.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
4.4.2. Storage & Retention
4.4.2.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
4.4.3. Packaging, Labeling, And Blinding
4.4.3.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
4.4.4. Manufacturing
4.4.4.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
4.4.5. Comparator Sourcing
4.4.5.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
4.4.6. Other
4.4.6.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
Chapter 5. Clinical Trial Supply & Logistics: Phase Estimates & Trend Analysis
5.1. Phase Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. Global Clinical Trial Supply & Logistics Market By Phase Outlook
5.4. Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Following
5.4.1. Phase I
5.4.1.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
5.4.2. Phase II
5.4.2.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
5.4.3. Phase III
5.4.3.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
5.4.4. Phase IV
5.4.4.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
Chapter 6. Clinical Trial Supply & Logistics: Therapeutic Area Estimates & Trend Analysis
6.1. Therapeutic Area Market Share, 2023 & 2030
6.2. Segment Dashboard
6.3. Global Clinical Trial Supply & Logistics Market By Therapeutic Area Outlook
6.4. Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Following
6.4.1. Oncology
6.4.1.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
6.4.2. Central Nervous System (CNS) Disorders
6.4.2.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
6.4.3. Cardiovascular Diseases
6.4.3.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
6.4.4. Respiratory Diseases
6.4.4.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
6.4.5. Others
6.4.5.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
Chapter 7. Clinical Trial Supply & Logistics: End Use Estimates & Trend Analysis
7.1. End use Market Share, 2023 & 2030
7.2. Segment Dashboard
7.3. Global Clinical Trial Supply & Logistics Market By End use Area Outlook
7.4. Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Following
7.4.1. Pharmaceutical
7.4.1.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
7.4.2. Biologicals
7.4.2.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
7.4.3. Medical Devices
7.4.3.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
Chapter 8. Regional Business Analysis
8.1. Regional Market Share Analysis, 2023 & 2030
8.2. Regional Market Dashboard
8.3. Global Regional Market Snapshot
8.4. Marker Size, & Forecasts Trend Analysis, 2018 To 2030:
8.5. North America
8.5.1. U.S.
8.5.1.1. Key Country Dynamics
8.5.1.2. Competitive Scenario
8.5.1.3. Regulatory Framework
8.5.1.4. U.S. Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.5.2. Canada
8.5.2.1. Key Country Dynamics
8.5.2.2. Competitive Scenario
8.5.2.3. Regulatory Framework
8.5.2.4. Canada Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.6. Europe
8.6.1. UK
8.6.1.1. Key Country Dynamics
8.6.1.2. Competitive Scenario
8.6.1.3. Regulatory Framework
8.6.1.4. UK Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.6.2. Germany
8.6.2.1. Key Country Dynamics
8.6.2.2. Competitive Scenario
8.6.2.3. Regulatory Framework
8.6.2.4. Germany Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.6.3. Spain
8.6.3.1. Key Country Dynamics
8.6.3.2. Competitive Scenario
8.6.3.3. Regulatory Framework
8.6.3.4. Spain Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.6.4. France
8.6.4.1. Key Country Dynamics
8.6.4.2. Competitive Scenario
8.6.4.3. Regulatory Framework
8.6.4.4. France Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.6.5. Italy
8.6.5.1. Key Country Dynamics
8.6.5.2. Competitive Scenario
8.6.5.3. Regulatory Framework
8.6.5.4. Italy Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.6.6. Denmark
8.6.6.1. Key Country Dynamics
8.6.6.2. Competitive Scenario
8.6.6.3. Regulatory Framework
8.6.6.4. Denmark Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.6.7. Sweden
8.6.7.1. Key Country Dynamics
8.6.7.2. Competitive Scenario
8.6.7.3. Regulatory Framework
8.6.7.4. Sweden Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.6.8. Norway
8.6.8.1. Key Country Dynamics
8.6.8.2. Competitive Scenario
8.6.8.3. Regulatory Framework
8.6.8.4. Norway Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.7. Asia Pacific
8.7.1. JAPAN
8.7.1.1. Key Country Dynamics
8.7.1.2. Competitive Scenario
8.7.1.3. Regulatory Framework
8.7.1.4. Japan Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.7.2. China
8.7.2.1. Key Country Dynamics
8.7.2.2. Competitive Scenario
8.7.2.3. Regulatory Framework
8.7.2.4. China Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.7.3. India
8.7.3.1. Key Country Dynamics
8.7.3.2. Competitive Scenario
8.7.3.3. Regulatory Framework
8.7.3.4. India Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.7.4. South Korea
8.7.4.1. Key Country Dynamics
8.7.4.2. Competitive Scenario
8.7.4.3. Regulatory Framework
8.7.4.4. South Korea Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.7.5. Thailand
8.7.5.1. Key Country Dynamics
8.7.5.2. Competitive Scenario
8.7.5.3. Regulatory Framework
8.7.5.4. Thailand Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.7.6. Australia
8.7.6.1. Key Country Dynamics
8.7.6.2. Competitive Scenario
8.7.6.3. Regulatory Framework
8.7.6.4. Australia Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.8. Latin America
8.8.1. Brazil
8.8.1.1. Key Country Dynamics
8.8.1.2. Competitive Scenario
8.8.1.3. Regulatory Framework
8.8.1.4. Brazil Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.8.2. Mexico
8.8.2.1. Key Country Dynamics
8.8.2.2. Competitive Scenario
8.8.2.3. Regulatory Framework
8.8.2.4. Mexico Clinical Trial Supply & Logistics Market, 2018 - 2030 (USD Million)
8.8.3. Argentina
8.8.3.1. Key Country Dynamics
8.8.3.2. Competitive Scenario
8.8.3.3. Regulatory Framework
8.8.3.4. Argentina Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.9. MEA
8.9.1. MEA Clinical Trial Supply & Logistics Market, 2018 - 2030 (USD Million)
8.9.2. South Africa
8.9.2.1. Key Country Dynamics
8.9.2.2. Competitive Scenario
8.9.2.3. Regulatory Framework
8.9.2.4. South Africa Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.9.3. Saudi Arabia
8.9.3.1. Key Country Dynamics
8.9.3.2. Competitive Scenario
8.9.3.3. Regulatory Framework
8.9.3.4. Saudi Arabia Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.9.4. UAE
8.9.4.1. Key Country Dynamics
8.9.4.2. Competitive Scenario
8.9.4.3. Regulatory Framework
8.9.4.4. UAE Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.9.5. Kuwait
8.9.5.1. Key Country Dynamics
8.9.5.2. Competitive Scenario
8.9.5.3. Regulatory Framework
8.9.5.4. Kuwait Market Estimates And Forecasts 2018 To 2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Recent Developments & Impact Analysis, By Key Market Participants
9.2. Company /Competition Categorization
9.3. Vendor Landscape
9.3.1. List Of Key Distributors And Channel Partners
9.3.2. Key Customers
9.3.3. Key Company Market Share Analysis, 2023
9.3.4. Thermo Fisher Scientific (Patheon)
9.3.4.1. Overview
9.3.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.4.3. Product Benchmarking
9.3.4.4. Strategic Initiatives
9.3.5. Catalent, Inc.
9.3.5.1. Overview
9.3.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.5.3. Product Benchmarking
9.3.5.4. Strategic Initiatives
9.3.6. Parexel International (MA) Corporation
9.3.6.1. Overview
9.3.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.6.3. Product Benchmarking
9.3.6.4. Strategic Initiatives
9.3.7. Almac Group
9.3.7.1. Overview
9.3.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.7.3. Product Benchmarking
9.3.7.4. Strategic Initiatives
9.3.8. Marken
9.3.8.1. Overview
9.3.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.8.3. Product Benchmarking
9.3.8.4. Strategic Initiatives
9.3.9. Piramal Pharma Solutions
9.3.9.1. Overview
9.3.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.9.3. Product Benchmarking
9.3.9.4. Strategic Initiatives
9.3.10. UDG HEALTHCARE
9.3.10.1. Overview
9.3.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.10.3. Product Benchmarking
9.3.10.4. Strategic Initiatives
9.3.11. DHL
9.3.11.1. Overview
9.3.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.11.3. Product Benchmarking
9.3.11.4. Strategic Initiatives
9.3.12. FedEx
9.3.12.1. Overview
9.3.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.12.3. Product Benchmarking
9.3.12.4. Strategic Initiatives
9.3.13. Movianto
9.3.13.1. Overview
9.3.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.13.3. Product Benchmarking
9.3.13.4. Strategic Initiatives
9.3.14. Packaging Coordinators Inc
9.3.14.1. Overview
9.3.14.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.14.3. Product Benchmarking
9.3.14.4. Strategic Initiatives





 

ページTOPに戻る


 

Summary

Clinical Trials Supply & Logistics Market Growth & Trends

The global clinical trials supply & logistics market size is expected to reach USD 6.25 billion by 2030, registering a CAGR of 7.6% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rise in advanced technology and innovations in the clinical trial supply & logistics market, implementation of stringent regulations, and the rising demand for clinical trials due to the increasing prevalence of diseases such as the COVID-19 pandemic.

Initially, the COVID-19 pandemic negatively impacted the market due to disruption in the supply chain and a reduction in commercial airlines by the government to prevent the spread of the virus. However, the market soon recovered and started to grow significantly due to rising demand for the COVID-19 vaccine to prevent this disease. For instance, according to WHO, as of August 2, 2022, there are 169 vaccines in the clinical development stage and 198 vaccines in the preclinical phase.

There has been significant investment in supply chain management software by clinical trial supplies providers. Growing complexity in clinical trials and increased competition among market players are factors responsible for the adoption of new technologies in supply chain management. The need for software for inventory management, supply chain planning, and ancillary supply chain management is expected to grow, owing to the increasing adoption of new technologies by industry players.

Clinical Trials Supply & Logistics Market Report Highlights

• In service segment, logistics & distribution dominated the market in 2023 with a share of 25.33%. This is due to the rise in clinical trials due to COVID- 19 pandemic

• Based on phase, The phase III segment accounted for the largest revenue share in 2023

• Based on therapeutic area, cardiovascular diseases accounted for the fastest CAGR of 8.0% during the forecast period. This is due to the rise in the number of investments by market players for bringing novel and innovation to the market

• Asia Pacific is anticipated to register the fastest growth rate of 8.1% during the forecast period. This is due to low recruitment cost, region has access to a large and diversified patient pool, and favorable policies that make the region desirable for clinical trials



ページTOPに戻る


Table of Contents

Table of Contents

Chapter 1. Methodology And Scope
1.1. Market Segmentation And Scope
1.1.1. Segment Definitions
1.1.1.1. Service Segment
1.1.1.2. Phase Segment
1.1.1.3. Therapeutics Area Segment
1.1.1.4. End use segment
1.2. Regional Scope
1.3. Estimates And Forecast Timeline
1.4. Objectives
1.4.1. Objective - 1
1.4.2. Objective - 2
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. GVR’s Internal Database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information Or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.10. List Of Primary Sources
1.11. List Of Abbreviations
Chapter 2. Clinical Trial Supply & Logistics Market: Executive Summary
2.1. Market Snapshot
2.2. Services And Phase Snapshots
2.3. Therapeutic Area And End Use Snapshot
2.4. Competitive Landscape Snapshot
Chapter 3. Clinical Trial Supply & Logistics Market Variables, Trends, & Scope
3.1. Market Segmentation And Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.4. Market Drivers Analysis
3.4.1. Technological advancements in supply chain
3.4.2. Increasing R&D investment by pharmaceutical and biopharmaceutical firms
3.4.3. Expansion of clinical trial sites
3.5. Market Restraint Analysis
3.5.1. Stringent regulation pertaining to logistics.
3.5.2. Counterfeiting of drugs
3.6. Clinical Trial Supply & Logistics Market Analysis Tools
3.6.1. Industry Analysis - Porter’s
3.6.1.1. Supplier Power
3.6.1.2. Buyer Power
3.6.1.3. Substitution Threat
3.6.1.4. Threat Of New Entrant
3.6.1.5. Competitive Rivalry
3.6.2. PESTLE Analysis
3.6.2.1. Political Landscape
3.6.2.2. Technological Landscape
3.6.2.3. Economic Landscape
Chapter 4. Clinical Trial Supply & Logistics: Service Estimates & Trend Analysis
4.1. Service Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. Global Clinical Trial Supply & Logistics Market By Service Outlook
4.4. Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Following
4.4.1. Logistics & Distribution
4.4.1.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
4.4.2. Storage & Retention
4.4.2.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
4.4.3. Packaging, Labeling, And Blinding
4.4.3.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
4.4.4. Manufacturing
4.4.4.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
4.4.5. Comparator Sourcing
4.4.5.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
4.4.6. Other
4.4.6.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
Chapter 5. Clinical Trial Supply & Logistics: Phase Estimates & Trend Analysis
5.1. Phase Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. Global Clinical Trial Supply & Logistics Market By Phase Outlook
5.4. Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Following
5.4.1. Phase I
5.4.1.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
5.4.2. Phase II
5.4.2.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
5.4.3. Phase III
5.4.3.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
5.4.4. Phase IV
5.4.4.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
Chapter 6. Clinical Trial Supply & Logistics: Therapeutic Area Estimates & Trend Analysis
6.1. Therapeutic Area Market Share, 2023 & 2030
6.2. Segment Dashboard
6.3. Global Clinical Trial Supply & Logistics Market By Therapeutic Area Outlook
6.4. Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Following
6.4.1. Oncology
6.4.1.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
6.4.2. Central Nervous System (CNS) Disorders
6.4.2.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
6.4.3. Cardiovascular Diseases
6.4.3.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
6.4.4. Respiratory Diseases
6.4.4.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
6.4.5. Others
6.4.5.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
Chapter 7. Clinical Trial Supply & Logistics: End Use Estimates & Trend Analysis
7.1. End use Market Share, 2023 & 2030
7.2. Segment Dashboard
7.3. Global Clinical Trial Supply & Logistics Market By End use Area Outlook
7.4. Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Following
7.4.1. Pharmaceutical
7.4.1.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
7.4.2. Biologicals
7.4.2.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
7.4.3. Medical Devices
7.4.3.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
Chapter 8. Regional Business Analysis
8.1. Regional Market Share Analysis, 2023 & 2030
8.2. Regional Market Dashboard
8.3. Global Regional Market Snapshot
8.4. Marker Size, & Forecasts Trend Analysis, 2018 To 2030:
8.5. North America
8.5.1. U.S.
8.5.1.1. Key Country Dynamics
8.5.1.2. Competitive Scenario
8.5.1.3. Regulatory Framework
8.5.1.4. U.S. Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.5.2. Canada
8.5.2.1. Key Country Dynamics
8.5.2.2. Competitive Scenario
8.5.2.3. Regulatory Framework
8.5.2.4. Canada Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.6. Europe
8.6.1. UK
8.6.1.1. Key Country Dynamics
8.6.1.2. Competitive Scenario
8.6.1.3. Regulatory Framework
8.6.1.4. UK Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.6.2. Germany
8.6.2.1. Key Country Dynamics
8.6.2.2. Competitive Scenario
8.6.2.3. Regulatory Framework
8.6.2.4. Germany Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.6.3. Spain
8.6.3.1. Key Country Dynamics
8.6.3.2. Competitive Scenario
8.6.3.3. Regulatory Framework
8.6.3.4. Spain Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.6.4. France
8.6.4.1. Key Country Dynamics
8.6.4.2. Competitive Scenario
8.6.4.3. Regulatory Framework
8.6.4.4. France Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.6.5. Italy
8.6.5.1. Key Country Dynamics
8.6.5.2. Competitive Scenario
8.6.5.3. Regulatory Framework
8.6.5.4. Italy Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.6.6. Denmark
8.6.6.1. Key Country Dynamics
8.6.6.2. Competitive Scenario
8.6.6.3. Regulatory Framework
8.6.6.4. Denmark Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.6.7. Sweden
8.6.7.1. Key Country Dynamics
8.6.7.2. Competitive Scenario
8.6.7.3. Regulatory Framework
8.6.7.4. Sweden Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.6.8. Norway
8.6.8.1. Key Country Dynamics
8.6.8.2. Competitive Scenario
8.6.8.3. Regulatory Framework
8.6.8.4. Norway Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.7. Asia Pacific
8.7.1. JAPAN
8.7.1.1. Key Country Dynamics
8.7.1.2. Competitive Scenario
8.7.1.3. Regulatory Framework
8.7.1.4. Japan Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.7.2. China
8.7.2.1. Key Country Dynamics
8.7.2.2. Competitive Scenario
8.7.2.3. Regulatory Framework
8.7.2.4. China Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.7.3. India
8.7.3.1. Key Country Dynamics
8.7.3.2. Competitive Scenario
8.7.3.3. Regulatory Framework
8.7.3.4. India Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.7.4. South Korea
8.7.4.1. Key Country Dynamics
8.7.4.2. Competitive Scenario
8.7.4.3. Regulatory Framework
8.7.4.4. South Korea Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.7.5. Thailand
8.7.5.1. Key Country Dynamics
8.7.5.2. Competitive Scenario
8.7.5.3. Regulatory Framework
8.7.5.4. Thailand Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.7.6. Australia
8.7.6.1. Key Country Dynamics
8.7.6.2. Competitive Scenario
8.7.6.3. Regulatory Framework
8.7.6.4. Australia Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.8. Latin America
8.8.1. Brazil
8.8.1.1. Key Country Dynamics
8.8.1.2. Competitive Scenario
8.8.1.3. Regulatory Framework
8.8.1.4. Brazil Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.8.2. Mexico
8.8.2.1. Key Country Dynamics
8.8.2.2. Competitive Scenario
8.8.2.3. Regulatory Framework
8.8.2.4. Mexico Clinical Trial Supply & Logistics Market, 2018 - 2030 (USD Million)
8.8.3. Argentina
8.8.3.1. Key Country Dynamics
8.8.3.2. Competitive Scenario
8.8.3.3. Regulatory Framework
8.8.3.4. Argentina Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.9. MEA
8.9.1. MEA Clinical Trial Supply & Logistics Market, 2018 - 2030 (USD Million)
8.9.2. South Africa
8.9.2.1. Key Country Dynamics
8.9.2.2. Competitive Scenario
8.9.2.3. Regulatory Framework
8.9.2.4. South Africa Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.9.3. Saudi Arabia
8.9.3.1. Key Country Dynamics
8.9.3.2. Competitive Scenario
8.9.3.3. Regulatory Framework
8.9.3.4. Saudi Arabia Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.9.4. UAE
8.9.4.1. Key Country Dynamics
8.9.4.2. Competitive Scenario
8.9.4.3. Regulatory Framework
8.9.4.4. UAE Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.9.5. Kuwait
8.9.5.1. Key Country Dynamics
8.9.5.2. Competitive Scenario
8.9.5.3. Regulatory Framework
8.9.5.4. Kuwait Market Estimates And Forecasts 2018 To 2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Recent Developments & Impact Analysis, By Key Market Participants
9.2. Company /Competition Categorization
9.3. Vendor Landscape
9.3.1. List Of Key Distributors And Channel Partners
9.3.2. Key Customers
9.3.3. Key Company Market Share Analysis, 2023
9.3.4. Thermo Fisher Scientific (Patheon)
9.3.4.1. Overview
9.3.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.4.3. Product Benchmarking
9.3.4.4. Strategic Initiatives
9.3.5. Catalent, Inc.
9.3.5.1. Overview
9.3.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.5.3. Product Benchmarking
9.3.5.4. Strategic Initiatives
9.3.6. Parexel International (MA) Corporation
9.3.6.1. Overview
9.3.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.6.3. Product Benchmarking
9.3.6.4. Strategic Initiatives
9.3.7. Almac Group
9.3.7.1. Overview
9.3.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.7.3. Product Benchmarking
9.3.7.4. Strategic Initiatives
9.3.8. Marken
9.3.8.1. Overview
9.3.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.8.3. Product Benchmarking
9.3.8.4. Strategic Initiatives
9.3.9. Piramal Pharma Solutions
9.3.9.1. Overview
9.3.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.9.3. Product Benchmarking
9.3.9.4. Strategic Initiatives
9.3.10. UDG HEALTHCARE
9.3.10.1. Overview
9.3.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.10.3. Product Benchmarking
9.3.10.4. Strategic Initiatives
9.3.11. DHL
9.3.11.1. Overview
9.3.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.11.3. Product Benchmarking
9.3.11.4. Strategic Initiatives
9.3.12. FedEx
9.3.12.1. Overview
9.3.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.12.3. Product Benchmarking
9.3.12.4. Strategic Initiatives
9.3.13. Movianto
9.3.13.1. Overview
9.3.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.13.3. Product Benchmarking
9.3.13.4. Strategic Initiatives
9.3.14. Packaging Coordinators Inc
9.3.14.1. Overview
9.3.14.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.14.3. Product Benchmarking
9.3.14.4. Strategic Initiatives





 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(医療機器)の最新刊レポート

Grand View Research社の医療機器分野での最新刊レポート


よくあるご質問


Grand View Research社はどのような調査会社ですか?


グランドビューリサーチ(Grand View Research)は通信技術、化学品、材料、ヘルスケア、エネルギーなど広範な市場を対象にした調査報告書を出版しています。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/22 10:26

155.52 円

163.34 円

198.56 円

ページTOPに戻る